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The hydrophobic estradiol-derivative RU49953 inhibits the energy-dependent interaction of yeast multidrug-transporter Pdr5p with
its fluorescent drug–substrate rhodamine 6G. The potent inhibition is competitive towards drug binding (Ki = 23F 6 nM), whereas
nucleoside-triphosphate hydrolysis is two-orders-of-magnitude less sensitive. RU49953 constitutes the most efficient inhibitor of drug
binding to a yeast multidrug ABC exporter reported so far.D 2003 Elsevier B.V. All rights reserved.Keywords: RU49953; Steroid; Pdr5p; Saccharomyces cerevisiae; Drug transport; ATPase1. Introduction
The major multidrug exporter of the yeast Saccharo-
myces cerevisiae is the full-size ABC (ATP-binding cas-
sette) transporter Pdr5p [1]. Its topology is different from
that of the mammalian P-glycoprotein in that each of the
two cytosolic nucleotide-binding domains is located at the
N-terminal side relative to each transmembrane domain
[2,3]. Moreover, several important amino acid substitu-
tions are observed in the ATP-binding motifs [2,4].
Nevertheless, Pdr5p interacts with a number of P-glyco-
protein substrates [5,6] and modulators such as flavonoids
[7] and protein kinase C effectors [8].
Pdr5p-enriched plasma membranes exhibit high ATPase
and UTPase activities [9]. In such membranes, the MgATP-0005-2736/03/$ - see front matter D 2003 Elsevier B.V. All rights reserved.
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conveniently monitored by quenching of the probe fluores-
cence. Interaction of multiple drugs, characterized by
alteration of rhodamine fluorescence quenching, correlates
to the drug-resistance properties of Pdr5p-overexpressing
yeast cells [5].
Steroids are transported in vivo by Pdr5p and
homologous transporters in S. cerevisiae [5,6,10,11]
and Candida albicans [12]. In isolated plasma mem-
branes, micromolar concentrations of progesterone and
derivatives, as well as of estradiol and deoxycorticoster-
one [5,7], inhibit the ATP-dependent drug-pumping
activity of Pdr5p. Mammalian P-glycoprotein is also
known to transport a number of hydroxylated steroids
[13–15], whereas more hydrophobic compounds, such
as progesterone [16,17], its RU38486 derivative [18,19]
and the RU49953 estradiol derivative [20], are not
transported by P-glycoprotein but inhibit its drug-pump-
ing activity.
The present results show that RU49953 constitutes the
highest, competitive, inhibitor of Pdr5p interaction with
rhodamine 6G ever reported. In addition, it produces a
Fig. 1. Inhibition of the energy-dependent interaction of rhodamine 6G with
Pdr5p. Pdr5p-enriched plasma membranes were incubated with 144 nM
rhodamine 6G and increasing concentrations of RU49953 (y) or RU38486
(.), or other derivatives such as RU39616 (w ), RU48659 (o), RU50641
(n), RU39411 (5) or R1881 (z). The reaction was initiated by the addition
of 4.8 mM MgCl2 and 4.8 mM ATP, and followed by monitoring the
decrease in fluorescence. The IC50 values of rhodamine 6G quenching were
determined using the Grafit program (Erithacus software).
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hydrolysis.2. Materials and methods
Steroid derivatives were obtained as previously [20,21].
ATP and UTP were purchased from Sigma, and rhodamine
6G from Merck. Pdr5p-enriched plasma membranes were
prepared from the yeast S. cerevisiae mutant AD124567
[22] as already reported [7,8].
Energy-dependent quenching of rhodamine 6G fluores-
cence and nucleoside-triphosphate hydrolytic activity within
Pdr5p-enriched yeast plasma membranes were assayed as
previously [5,7]. Briefly, Pdr5p-enriched plasma membranes
(70–130 Ag of protein) were incubated at 30 jC in 2 ml of
50 mM Hepes, pH 7.0, in the presence of rhodamine 6G.
The reaction was initiated by 4.4 mM ATP. The decrease in
fluorescence at 552 nm was recorded for 20–40 min afterFig. 2. Chemical structures of the progesterone derivative RU38486 and the es
propynyl derivative of progesterone whereas the even more hydrophobic RU499steroid addition, and the linear initial slope was estimated.
ATPase and UTPase activities were measured by incubating
Pdr5p-enriched membranes (10–20 Ag of protein) at 35 jC
in 500 Al of 50 mM MES, pH 7.5, containing 0.3 mM
ammonium heptamolybdate, 75 mM potassium nitrate and
7.5 mM sodium azide, in the presence of 6 mM of both
MgCl2 and either ATP or UTP. After 5–15 min, the reaction
was stopped by trichloroacetic acid, and the released inor-
ganic phosphate was titrated. Steroid derivatives were added
from stock solutions in dimethylsulfoxide, up to a 2–4%
(v/v) final concentration.3. Results and discussion
Fig. 1 shows that the hydrophobic estradiol-derivative
RU49953, whose structure is shown in Fig. 2, strongly
inhibited the energy-dependent rhodamine 6G interaction
with Pdr5p. The IC50 (inhibitor concentration producing
50% inhibition) was 0.083F 0.007 AM for RU49953,
whereas a lower-affinity inhibition was observed for
RU38486 (IC50 = 0.54F 0.03 AM). All the other tested
derivatives were less efficient than RU38486, with the
exception of RU39616 (an RU38486 analogue with double
bonds at positions 5 and 9, instead of 4 and 10), which
behaved similarly (IC50 = 0.45F 0.03 AM). Those com-
pounds included RU48659, an estradiol derivative with a
dimethylaminophenyl at position 7 (IC50 = 0.70F 0.05 AM),
RU50641, an RU38486 derivative with a dimethylamino-
phenyl at position 7, instead of 11, and without substitution
at position 17 (IC50 = 1.06F 0.11 AM), and RU39411, an
estradiol derivative with a modified dimethylaminophenyl at
position 11 (IC50 = 1.9F 0.2 AM). The less efficient com-
pound, R1881 (an 38486 derivative without substitution at
position 11), hardly inhibited at 2 AM (< 10%) as its IC50
value was higher than 25 AM.
As similar structure–activity relationships were obtained
previously on P-glycoprotein overexpressing NIH3T3 cells
towards growth chemosensitization to vinblastine [20], it
appears that mammalian P-glycoprotein and yeast Pdr5p
obey similar mechanisms for interaction with drugs even
though their different topology has justified their classifica-
tion in the phylogenetic families B and G, respectively, oftradiol derivative RU49953. RU38486 is a 11-dimethylaminophenyl, 17-
53 is a 11,17-di(dimethylaminophenyl) derivative of estradiol.
Fig. 4. Inhibition of Pdr5p nucleoside-triphosphate hydrolytic activity. The
Pdr5p-enriched plasma membranes were incubated in the presence of either
RU49953 (o,5) or RU38486 (.), and the reaction was started by the
addition of 6 mM of either UTP (o,.) or ATP (5), and excess MgCl2
providing 1 mM free Mg2 +; released phosphate was titrated colorimetrically.
Inset: type of RU49953 inhibition on UTPase activity; membranes were
incubated with the estradiol derivative at either 0 (z), 2 (q), 5 (E) or 10
(D) AM, and assayed with increasing UTP concentrations as indicated.
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observation that Pdr5p is sensitive to many substrates and
modulators, including steroids, known to interact with P-
glycoprotein [5,6]. When concentrations of both rhodamine
6G and RU49953 were varied in the nanomolar range (Fig.
3), the competitive inhibition produced by the estradiol
analogue allowed to determine a very low Ki value from
Dixon plots (23F 6 nM) indicative of an extremely high-
affinity interaction at the rhodamine 6G-binding sites. To
our knowledge, this constitutes the highest affinity ever
reported for a Pdr5p inhibitor. Indeed, natural steroids were
found to be two-orders-of-magnitude less efficient [5], and
lower-affinity inhibitions were also observed with either
flavonoids [7], protein kinase C effectors [8] or a variety of
other compounds [6].
In contrast, much higher concentrations of steroids were
required to inhibit UTPase activity (Fig. 4): an IC50 value
of 3.6F 0.24 AM was obtained for RU49953, while the
progesterone derivative, RU38486, was less efficient
(IC50 = 7.5F 0.67 AM). Curiously, the ATPase activity of
Pdr5p was even less sensitive to steroid inhibition than
UTPase (IC50 = 10.0F 1.5 AM). A similar differential sen-
sitivity to inhibition between UTPase and ATPase activities
was already observed with prenylflavonoids [7,23] and
protein kinase C effectors [8], and UTP was much less
efficient than ATP to promote rhodamine 6G transport [5].
Inhibition of nucleoside-triphosphate hydrolysis by steroids
was further analyzed by varying the concentrations of both
UTP and RU49953 (inset, Fig. 4), and found to be
noncompetitive.
The fact that RU49953 inhibited 400-fold better drug
transport than ATP-driven energy production indicates that
RU49953 interacts with high affinity at the drug-binding
sites within the transmembrane domain of Pdr5p. Such a
binding might have been expected to stimulate nucleoside-
triphosphate hydrolysis as observed for P-glycoprotein [24].Fig. 3. Type of inhibition by RU49953 of the energy-dependent interaction
of rhodamine 6G with Pdr5p. Membranes were incubated, under the same
conditions as in Fig. 1, with the indicated RU49953 concentrations in the
presence of rhodamine 6G at either 10 (n), 25 (5), 50 (.) or 100 (o) nM,
before MgCl2 and ATP addition.This was not the case here for Pdr5p with RU49953, as
previously with flavonoids [7,23] and protein kinase C
derivatives [8]. This Pdr5p behavior might be related to
the probable lack of two fully functional hydrolytic sites [2].
Indeed, in bacterial ABC transporters, the Walker motifs A
and B of the N-terminal nucleotide-binding domain together
with the motif C/ABC signature of the C-terminal domain
bind the same ATP molecule, as demonstrated in the crystal
structure of MJ0796 [25]. The putative hydrolytic deficien-
cy in one ATP-binding site of Pdr5p and of all full-size
members of the G family (so far restricted to the fungi and
plant kingdoms) of the ABC transporters superfamily may
modify the coupling mechanism between ATP hydrolysis
and drug binding and transport.Acknowledgements
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